Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfredi Rizzo

Showing results (51-60 of 522) with videos related to

Pageof 53
Sort By:
Journal of Diabetes and Its Complications|June 29, 2023
GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanismsFernando Gómez-Peralta, Cristina Abreu, Manfredi Rizzo
Journal of Diabetes and Its Complications|July 22, 2024
Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitusDimitrios Patoulias, Ali H Eid, Manfredi Rizzo
Advances in Therapy|November 10, 2021
Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical PracticeAntonio Ceriello, Ali A Rizvi, Manfredi Rizzo
Advances in Therapy|July 31, 2007
Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patientsManfredi Rizzo, Giovam Battista Rini, Kaspar Berneis
Expert Opinion on Pharmacotherapy|March 29, 2014
Treatment options for managing atherogenic dyslipidemia and fatty liver diseaseManfredi Rizzo, Giuseppe Montalto, Khalid Al-Rasadi
Journal of Diabetes and Its Complications|November 12, 2023
GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?Emir Muzurović, Volkan Demirhan Yumuk, Manfredi Rizzo
Diabetology & Metabolic Syndrome|December 22, 2022
Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagonsAntonio E Pontiroli, Manfredi Rizzo, Elena Tagliabue
Diabetes, Obesity & Metabolism|January 19, 2017
Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetesManfredi Rizzo, Ali A Rizvi, Giorgio Sesti
Journal of Diabetes and Its Complications|March 5, 2023
Epicardial, peripancreatic and other "orthotopic" excessive fat deposition in south Asians and Europeans: Are differences clinically relevant?Niki Katsiki, Manfredi Rizzo, Dimitri P Mikhailidis
Metabolites|August 25, 2022
Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and TreatmentJelena Vekic, José Silva-Nunes, Manfredi Rizzo
Pageof 53

Showing results (51-60 of 522) with videos related to

Sort By:
Pageof 53
Journal of Diabetes and Its Complications|June 29, 2023
GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanismsFernando Gómez-Peralta, Cristina Abreu, Manfredi Rizzo
Journal of Diabetes and Its Complications|July 22, 2024
Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitusDimitrios Patoulias, Ali H Eid, Manfredi Rizzo
Advances in Therapy|November 10, 2021
Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical PracticeAntonio Ceriello, Ali A Rizvi, Manfredi Rizzo
Advances in Therapy|July 31, 2007
Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patientsManfredi Rizzo, Giovam Battista Rini, Kaspar Berneis
Expert Opinion on Pharmacotherapy|March 29, 2014
Treatment options for managing atherogenic dyslipidemia and fatty liver diseaseManfredi Rizzo, Giuseppe Montalto, Khalid Al-Rasadi
Journal of Diabetes and Its Complications|November 12, 2023
GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?Emir Muzurović, Volkan Demirhan Yumuk, Manfredi Rizzo
Diabetology & Metabolic Syndrome|December 22, 2022
Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagonsAntonio E Pontiroli, Manfredi Rizzo, Elena Tagliabue
Diabetes, Obesity & Metabolism|January 19, 2017
Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetesManfredi Rizzo, Ali A Rizvi, Giorgio Sesti
Journal of Diabetes and Its Complications|March 5, 2023
Epicardial, peripancreatic and other "orthotopic" excessive fat deposition in south Asians and Europeans: Are differences clinically relevant?Niki Katsiki, Manfredi Rizzo, Dimitri P Mikhailidis
Metabolites|August 25, 2022
Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and TreatmentJelena Vekic, José Silva-Nunes, Manfredi Rizzo
Pageof 53